Global Biopharmaceutical and Bio-CDMO Market 2026 by Company, Regions, Type and Application, Forecast to 2032
According to our (Global Info Research) latest study, the global Biopharmaceutical and Bio-CDMO market size was valued at US$ 32400 million in 2025 and is forecast to a readjusted size of US$ 74760 million by 2032 with a CAGR of 12.8% during review period.
Biopharmaceutical Contract Development and Manufacturing Organizations (CDMOs) are companies that provide comprehensive services for the development and manufacturing of biopharmaceutical products. These organizations play a crucial role in the biopharmaceutical industry by offering a range of services to biotech and pharmaceutical companies, allowing them to outsource various stages of the drug development and manufacturing process.
Increasing Demand for Biologics: The rising demand for biopharmaceuticals, including monoclonal antibodies, recombinant proteins, and gene therapies, is a significant driver. Biologics are increasingly becoming a focus for drug development due to their effectiveness in treating various diseases.
Cost-Effective Outsourcing: Outsourcing to CDMOs allows pharmaceutical and biotech companies to reduce capital expenditures, mitigate risks, and achieve cost savings. CDMOs offer specialized facilities and expertise, allowing clients to avoid the need for extensive in-house infrastructure.
Strategic Partnerships and Collaborations: Pharmaceutical and biotech companies increasingly engage in strategic partnerships with CDMOs to access specialized capabilities, share development risks, and benefit from the CDMO's expertise in specific technologies or therapeutic areas.
To meet the growing demand for biopharmaceuticals, CDMOs are investing in expanding their biomanufacturing capacities. This includes the construction of new facilities and the acquisition of advanced technologies to increase production capabilities.
The increasing interest and investment in cell and gene therapies have led to a rise in demand for CDMOs offering services in this area. Companies are seeking expertise in cell line development, viral vector production, and other specialized services related to advanced therapies.
Biopharmaceutical CDMOs are expanding their global presence to cater to the needs of a geographically diverse client base. This includes establishing facilities in key regions and forming strategic partnerships to enhance their global reach.
CDMOs are expanding their service offerings to provide integrated solutions covering the entire biopharmaceutical development and manufacturing lifecycle. This integrated approach aims to streamline processes and accelerate time to market for clients.
This report is a detailed and comprehensive analysis for global Biopharmaceutical and Bio-CDMO market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Biopharmaceutical and Bio-CDMO market size and forecasts, in consumption value ($ Million), 2021-2032
Global Biopharmaceutical and Bio-CDMO market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Biopharmaceutical and Bio-CDMO market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Biopharmaceutical and Bio-CDMO market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Biopharmaceutical and Bio-CDMO
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Biopharmaceutical and Bio-CDMO market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Lonza, Catalent, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Boehringer Ingelheim, WuXi Biologics, Recipharm, Thermo Fisher Scientific, AGC Biologics, Rentschler Biopharma, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Biopharmaceutical and Bio-CDMO market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Biopharmaceutical and Bio-CDMO product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Biopharmaceutical and Bio-CDMO, with revenue, gross margin, and global market share of Biopharmaceutical and Bio-CDMO from 2021 to 2026.
Chapter 3, the Biopharmaceutical and Bio-CDMO competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Biopharmaceutical and Bio-CDMO market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Biopharmaceutical and Bio-CDMO.
Chapter 13, to describe Biopharmaceutical and Bio-CDMO research findings and conclusion.
Biopharmaceutical Contract Development and Manufacturing Organizations (CDMOs) are companies that provide comprehensive services for the development and manufacturing of biopharmaceutical products. These organizations play a crucial role in the biopharmaceutical industry by offering a range of services to biotech and pharmaceutical companies, allowing them to outsource various stages of the drug development and manufacturing process.
Increasing Demand for Biologics: The rising demand for biopharmaceuticals, including monoclonal antibodies, recombinant proteins, and gene therapies, is a significant driver. Biologics are increasingly becoming a focus for drug development due to their effectiveness in treating various diseases.
Cost-Effective Outsourcing: Outsourcing to CDMOs allows pharmaceutical and biotech companies to reduce capital expenditures, mitigate risks, and achieve cost savings. CDMOs offer specialized facilities and expertise, allowing clients to avoid the need for extensive in-house infrastructure.
Strategic Partnerships and Collaborations: Pharmaceutical and biotech companies increasingly engage in strategic partnerships with CDMOs to access specialized capabilities, share development risks, and benefit from the CDMO's expertise in specific technologies or therapeutic areas.
To meet the growing demand for biopharmaceuticals, CDMOs are investing in expanding their biomanufacturing capacities. This includes the construction of new facilities and the acquisition of advanced technologies to increase production capabilities.
The increasing interest and investment in cell and gene therapies have led to a rise in demand for CDMOs offering services in this area. Companies are seeking expertise in cell line development, viral vector production, and other specialized services related to advanced therapies.
Biopharmaceutical CDMOs are expanding their global presence to cater to the needs of a geographically diverse client base. This includes establishing facilities in key regions and forming strategic partnerships to enhance their global reach.
CDMOs are expanding their service offerings to provide integrated solutions covering the entire biopharmaceutical development and manufacturing lifecycle. This integrated approach aims to streamline processes and accelerate time to market for clients.
This report is a detailed and comprehensive analysis for global Biopharmaceutical and Bio-CDMO market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Biopharmaceutical and Bio-CDMO market size and forecasts, in consumption value ($ Million), 2021-2032
Global Biopharmaceutical and Bio-CDMO market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Biopharmaceutical and Bio-CDMO market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Biopharmaceutical and Bio-CDMO market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Biopharmaceutical and Bio-CDMO
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Biopharmaceutical and Bio-CDMO market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Lonza, Catalent, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Boehringer Ingelheim, WuXi Biologics, Recipharm, Thermo Fisher Scientific, AGC Biologics, Rentschler Biopharma, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Biopharmaceutical and Bio-CDMO market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Cell and Gene Therapies
- Antibodies
- Vaccines
- Other
- SMBs
- Large Companies
- Lonza
- Catalent
- Samsung Biologics
- FUJIFILM Diosynth Biotechnologies
- Boehringer Ingelheim
- WuXi Biologics
- Recipharm
- Thermo Fisher Scientific
- AGC Biologics
- Rentschler Biopharma
- KBI Biopharma
- Siegfried
- Aenova Group
- GenScript
- ProBioGen
- Northway Biotech
- 3P Biopharmaceuticals
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Biopharmaceutical and Bio-CDMO product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Biopharmaceutical and Bio-CDMO, with revenue, gross margin, and global market share of Biopharmaceutical and Bio-CDMO from 2021 to 2026.
Chapter 3, the Biopharmaceutical and Bio-CDMO competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Biopharmaceutical and Bio-CDMO market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Biopharmaceutical and Bio-CDMO.
Chapter 13, to describe Biopharmaceutical and Bio-CDMO research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Biopharmaceutical and Bio-CDMO by Type
1.3.1 Overview: Global Biopharmaceutical and Bio-CDMO Market Size by Type: 2021 Versus 2025 Versus 2032
1.3.2 Global Biopharmaceutical and Bio-CDMO Consumption Value Market Share by Type in 2025
1.3.3 Cell and Gene Therapies
1.3.4 Antibodies
1.3.5 Vaccines
1.3.6 Other
1.4 Global Biopharmaceutical and Bio-CDMO Market by Application
1.4.1 Overview: Global Biopharmaceutical and Bio-CDMO Market Size by Application: 2021 Versus 2025 Versus 2032
1.4.2 SMBs
1.4.3 Large Companies
1.5 Global Biopharmaceutical and Bio-CDMO Market Size & Forecast
1.6 Global Biopharmaceutical and Bio-CDMO Market Size and Forecast by Region
1.6.1 Global Biopharmaceutical and Bio-CDMO Market Size by Region: 2021 VS 2025 VS 2032
1.6.2 Global Biopharmaceutical and Bio-CDMO Market Size by Region, (2021-2032)
1.6.3 North America Biopharmaceutical and Bio-CDMO Market Size and Prospect (2021-2032)
1.6.4 Europe Biopharmaceutical and Bio-CDMO Market Size and Prospect (2021-2032)
1.6.5 Asia-Pacific Biopharmaceutical and Bio-CDMO Market Size and Prospect (2021-2032)
1.6.6 South America Biopharmaceutical and Bio-CDMO Market Size and Prospect (2021-2032)
1.6.7 Middle East & Africa Biopharmaceutical and Bio-CDMO Market Size and Prospect (2021-2032)
2 COMPANY PROFILES
2.1 Lonza
2.1.1 Lonza Details
2.1.2 Lonza Major Business
2.1.3 Lonza Biopharmaceutical and Bio-CDMO Product and Solutions
2.1.4 Lonza Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Lonza Recent Developments and Future Plans
2.2 Catalent
2.2.1 Catalent Details
2.2.2 Catalent Major Business
2.2.3 Catalent Biopharmaceutical and Bio-CDMO Product and Solutions
2.2.4 Catalent Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Catalent Recent Developments and Future Plans
2.3 Samsung Biologics
2.3.1 Samsung Biologics Details
2.3.2 Samsung Biologics Major Business
2.3.3 Samsung Biologics Biopharmaceutical and Bio-CDMO Product and Solutions
2.3.4 Samsung Biologics Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Samsung Biologics Recent Developments and Future Plans
2.4 FUJIFILM Diosynth Biotechnologies
2.4.1 FUJIFILM Diosynth Biotechnologies Details
2.4.2 FUJIFILM Diosynth Biotechnologies Major Business
2.4.3 FUJIFILM Diosynth Biotechnologies Biopharmaceutical and Bio-CDMO Product and Solutions
2.4.4 FUJIFILM Diosynth Biotechnologies Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 FUJIFILM Diosynth Biotechnologies Recent Developments and Future Plans
2.5 Boehringer Ingelheim
2.5.1 Boehringer Ingelheim Details
2.5.2 Boehringer Ingelheim Major Business
2.5.3 Boehringer Ingelheim Biopharmaceutical and Bio-CDMO Product and Solutions
2.5.4 Boehringer Ingelheim Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 Boehringer Ingelheim Recent Developments and Future Plans
2.6 WuXi Biologics
2.6.1 WuXi Biologics Details
2.6.2 WuXi Biologics Major Business
2.6.3 WuXi Biologics Biopharmaceutical and Bio-CDMO Product and Solutions
2.6.4 WuXi Biologics Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 WuXi Biologics Recent Developments and Future Plans
2.7 Recipharm
2.7.1 Recipharm Details
2.7.2 Recipharm Major Business
2.7.3 Recipharm Biopharmaceutical and Bio-CDMO Product and Solutions
2.7.4 Recipharm Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Recipharm Recent Developments and Future Plans
2.8 Thermo Fisher Scientific
2.8.1 Thermo Fisher Scientific Details
2.8.2 Thermo Fisher Scientific Major Business
2.8.3 Thermo Fisher Scientific Biopharmaceutical and Bio-CDMO Product and Solutions
2.8.4 Thermo Fisher Scientific Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 Thermo Fisher Scientific Recent Developments and Future Plans
2.9 AGC Biologics
2.9.1 AGC Biologics Details
2.9.2 AGC Biologics Major Business
2.9.3 AGC Biologics Biopharmaceutical and Bio-CDMO Product and Solutions
2.9.4 AGC Biologics Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 AGC Biologics Recent Developments and Future Plans
2.10 Rentschler Biopharma
2.10.1 Rentschler Biopharma Details
2.10.2 Rentschler Biopharma Major Business
2.10.3 Rentschler Biopharma Biopharmaceutical and Bio-CDMO Product and Solutions
2.10.4 Rentschler Biopharma Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 Rentschler Biopharma Recent Developments and Future Plans
2.11 KBI Biopharma
2.11.1 KBI Biopharma Details
2.11.2 KBI Biopharma Major Business
2.11.3 KBI Biopharma Biopharmaceutical and Bio-CDMO Product and Solutions
2.11.4 KBI Biopharma Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2021-2026)
2.11.5 KBI Biopharma Recent Developments and Future Plans
2.12 Siegfried
2.12.1 Siegfried Details
2.12.2 Siegfried Major Business
2.12.3 Siegfried Biopharmaceutical and Bio-CDMO Product and Solutions
2.12.4 Siegfried Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2021-2026)
2.12.5 Siegfried Recent Developments and Future Plans
2.13 Aenova Group
2.13.1 Aenova Group Details
2.13.2 Aenova Group Major Business
2.13.3 Aenova Group Biopharmaceutical and Bio-CDMO Product and Solutions
2.13.4 Aenova Group Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2021-2026)
2.13.5 Aenova Group Recent Developments and Future Plans
2.14 GenScript
2.14.1 GenScript Details
2.14.2 GenScript Major Business
2.14.3 GenScript Biopharmaceutical and Bio-CDMO Product and Solutions
2.14.4 GenScript Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2021-2026)
2.14.5 GenScript Recent Developments and Future Plans
2.15 ProBioGen
2.15.1 ProBioGen Details
2.15.2 ProBioGen Major Business
2.15.3 ProBioGen Biopharmaceutical and Bio-CDMO Product and Solutions
2.15.4 ProBioGen Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2021-2026)
2.15.5 ProBioGen Recent Developments and Future Plans
2.16 Northway Biotech
2.16.1 Northway Biotech Details
2.16.2 Northway Biotech Major Business
2.16.3 Northway Biotech Biopharmaceutical and Bio-CDMO Product and Solutions
2.16.4 Northway Biotech Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2021-2026)
2.16.5 Northway Biotech Recent Developments and Future Plans
2.17 3P Biopharmaceuticals
2.17.1 3P Biopharmaceuticals Details
2.17.2 3P Biopharmaceuticals Major Business
2.17.3 3P Biopharmaceuticals Biopharmaceutical and Bio-CDMO Product and Solutions
2.17.4 3P Biopharmaceuticals Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2021-2026)
2.17.5 3P Biopharmaceuticals Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Biopharmaceutical and Bio-CDMO Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
3.2.1 Market Share of Biopharmaceutical and Bio-CDMO by Company Revenue
3.2.2 Top 3 Biopharmaceutical and Bio-CDMO Players Market Share in 2025
3.2.3 Top 6 Biopharmaceutical and Bio-CDMO Players Market Share in 2025
3.3 Biopharmaceutical and Bio-CDMO Market: Overall Company Footprint Analysis
3.3.1 Biopharmaceutical and Bio-CDMO Market: Region Footprint
3.3.2 Biopharmaceutical and Bio-CDMO Market: Company Product Type Footprint
3.3.3 Biopharmaceutical and Bio-CDMO Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Biopharmaceutical and Bio-CDMO Consumption Value and Market Share by Type (2021-2026)
4.2 Global Biopharmaceutical and Bio-CDMO Market Forecast by Type (2027-2032)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Biopharmaceutical and Bio-CDMO Consumption Value Market Share by Application (2021-2026)
5.2 Global Biopharmaceutical and Bio-CDMO Market Forecast by Application (2027-2032)
6 NORTH AMERICA
6.1 North America Biopharmaceutical and Bio-CDMO Consumption Value by Type (2021-2032)
6.2 North America Biopharmaceutical and Bio-CDMO Market Size by Application (2021-2032)
6.3 North America Biopharmaceutical and Bio-CDMO Market Size by Country
6.3.1 North America Biopharmaceutical and Bio-CDMO Consumption Value by Country (2021-2032)
6.3.2 United States Biopharmaceutical and Bio-CDMO Market Size and Forecast (2021-2032)
6.3.3 Canada Biopharmaceutical and Bio-CDMO Market Size and Forecast (2021-2032)
6.3.4 Mexico Biopharmaceutical and Bio-CDMO Market Size and Forecast (2021-2032)
7 EUROPE
7.1 Europe Biopharmaceutical and Bio-CDMO Consumption Value by Type (2021-2032)
7.2 Europe Biopharmaceutical and Bio-CDMO Consumption Value by Application (2021-2032)
7.3 Europe Biopharmaceutical and Bio-CDMO Market Size by Country
7.3.1 Europe Biopharmaceutical and Bio-CDMO Consumption Value by Country (2021-2032)
7.3.2 Germany Biopharmaceutical and Bio-CDMO Market Size and Forecast (2021-2032)
7.3.3 France Biopharmaceutical and Bio-CDMO Market Size and Forecast (2021-2032)
7.3.4 United Kingdom Biopharmaceutical and Bio-CDMO Market Size and Forecast (2021-2032)
7.3.5 Russia Biopharmaceutical and Bio-CDMO Market Size and Forecast (2021-2032)
7.3.6 Italy Biopharmaceutical and Bio-CDMO Market Size and Forecast (2021-2032)
8 ASIA-PACIFIC
8.1 Asia-Pacific Biopharmaceutical and Bio-CDMO Consumption Value by Type (2021-2032)
8.2 Asia-Pacific Biopharmaceutical and Bio-CDMO Consumption Value by Application (2021-2032)
8.3 Asia-Pacific Biopharmaceutical and Bio-CDMO Market Size by Region
8.3.1 Asia-Pacific Biopharmaceutical and Bio-CDMO Consumption Value by Region (2021-2032)
8.3.2 China Biopharmaceutical and Bio-CDMO Market Size and Forecast (2021-2032)
8.3.3 Japan Biopharmaceutical and Bio-CDMO Market Size and Forecast (2021-2032)
8.3.4 South Korea Biopharmaceutical and Bio-CDMO Market Size and Forecast (2021-2032)
8.3.5 India Biopharmaceutical and Bio-CDMO Market Size and Forecast (2021-2032)
8.3.6 Southeast Asia Biopharmaceutical and Bio-CDMO Market Size and Forecast (2021-2032)
8.3.7 Australia Biopharmaceutical and Bio-CDMO Market Size and Forecast (2021-2032)
9 SOUTH AMERICA
9.1 South America Biopharmaceutical and Bio-CDMO Consumption Value by Type (2021-2032)
9.2 South America Biopharmaceutical and Bio-CDMO Consumption Value by Application (2021-2032)
9.3 South America Biopharmaceutical and Bio-CDMO Market Size by Country
9.3.1 South America Biopharmaceutical and Bio-CDMO Consumption Value by Country (2021-2032)
9.3.2 Brazil Biopharmaceutical and Bio-CDMO Market Size and Forecast (2021-2032)
9.3.3 Argentina Biopharmaceutical and Bio-CDMO Market Size and Forecast (2021-2032)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Biopharmaceutical and Bio-CDMO Consumption Value by Type (2021-2032)
10.2 Middle East & Africa Biopharmaceutical and Bio-CDMO Consumption Value by Application (2021-2032)
10.3 Middle East & Africa Biopharmaceutical and Bio-CDMO Market Size by Country
10.3.1 Middle East & Africa Biopharmaceutical and Bio-CDMO Consumption Value by Country (2021-2032)
10.3.2 Turkey Biopharmaceutical and Bio-CDMO Market Size and Forecast (2021-2032)
10.3.3 Saudi Arabia Biopharmaceutical and Bio-CDMO Market Size and Forecast (2021-2032)
10.3.4 UAE Biopharmaceutical and Bio-CDMO Market Size and Forecast (2021-2032)
11 MARKET DYNAMICS
11.1 Biopharmaceutical and Bio-CDMO Market Drivers
11.2 Biopharmaceutical and Bio-CDMO Market Restraints
11.3 Biopharmaceutical and Bio-CDMO Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Biopharmaceutical and Bio-CDMO Industry Chain
12.2 Biopharmaceutical and Bio-CDMO Upstream Analysis
12.3 Biopharmaceutical and Bio-CDMO Midstream Analysis
12.4 Biopharmaceutical and Bio-CDMO Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Biopharmaceutical and Bio-CDMO by Type
1.3.1 Overview: Global Biopharmaceutical and Bio-CDMO Market Size by Type: 2021 Versus 2025 Versus 2032
1.3.2 Global Biopharmaceutical and Bio-CDMO Consumption Value Market Share by Type in 2025
1.3.3 Cell and Gene Therapies
1.3.4 Antibodies
1.3.5 Vaccines
1.3.6 Other
1.4 Global Biopharmaceutical and Bio-CDMO Market by Application
1.4.1 Overview: Global Biopharmaceutical and Bio-CDMO Market Size by Application: 2021 Versus 2025 Versus 2032
1.4.2 SMBs
1.4.3 Large Companies
1.5 Global Biopharmaceutical and Bio-CDMO Market Size & Forecast
1.6 Global Biopharmaceutical and Bio-CDMO Market Size and Forecast by Region
1.6.1 Global Biopharmaceutical and Bio-CDMO Market Size by Region: 2021 VS 2025 VS 2032
1.6.2 Global Biopharmaceutical and Bio-CDMO Market Size by Region, (2021-2032)
1.6.3 North America Biopharmaceutical and Bio-CDMO Market Size and Prospect (2021-2032)
1.6.4 Europe Biopharmaceutical and Bio-CDMO Market Size and Prospect (2021-2032)
1.6.5 Asia-Pacific Biopharmaceutical and Bio-CDMO Market Size and Prospect (2021-2032)
1.6.6 South America Biopharmaceutical and Bio-CDMO Market Size and Prospect (2021-2032)
1.6.7 Middle East & Africa Biopharmaceutical and Bio-CDMO Market Size and Prospect (2021-2032)
2 COMPANY PROFILES
2.1 Lonza
2.1.1 Lonza Details
2.1.2 Lonza Major Business
2.1.3 Lonza Biopharmaceutical and Bio-CDMO Product and Solutions
2.1.4 Lonza Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Lonza Recent Developments and Future Plans
2.2 Catalent
2.2.1 Catalent Details
2.2.2 Catalent Major Business
2.2.3 Catalent Biopharmaceutical and Bio-CDMO Product and Solutions
2.2.4 Catalent Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Catalent Recent Developments and Future Plans
2.3 Samsung Biologics
2.3.1 Samsung Biologics Details
2.3.2 Samsung Biologics Major Business
2.3.3 Samsung Biologics Biopharmaceutical and Bio-CDMO Product and Solutions
2.3.4 Samsung Biologics Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Samsung Biologics Recent Developments and Future Plans
2.4 FUJIFILM Diosynth Biotechnologies
2.4.1 FUJIFILM Diosynth Biotechnologies Details
2.4.2 FUJIFILM Diosynth Biotechnologies Major Business
2.4.3 FUJIFILM Diosynth Biotechnologies Biopharmaceutical and Bio-CDMO Product and Solutions
2.4.4 FUJIFILM Diosynth Biotechnologies Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 FUJIFILM Diosynth Biotechnologies Recent Developments and Future Plans
2.5 Boehringer Ingelheim
2.5.1 Boehringer Ingelheim Details
2.5.2 Boehringer Ingelheim Major Business
2.5.3 Boehringer Ingelheim Biopharmaceutical and Bio-CDMO Product and Solutions
2.5.4 Boehringer Ingelheim Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 Boehringer Ingelheim Recent Developments and Future Plans
2.6 WuXi Biologics
2.6.1 WuXi Biologics Details
2.6.2 WuXi Biologics Major Business
2.6.3 WuXi Biologics Biopharmaceutical and Bio-CDMO Product and Solutions
2.6.4 WuXi Biologics Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 WuXi Biologics Recent Developments and Future Plans
2.7 Recipharm
2.7.1 Recipharm Details
2.7.2 Recipharm Major Business
2.7.3 Recipharm Biopharmaceutical and Bio-CDMO Product and Solutions
2.7.4 Recipharm Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Recipharm Recent Developments and Future Plans
2.8 Thermo Fisher Scientific
2.8.1 Thermo Fisher Scientific Details
2.8.2 Thermo Fisher Scientific Major Business
2.8.3 Thermo Fisher Scientific Biopharmaceutical and Bio-CDMO Product and Solutions
2.8.4 Thermo Fisher Scientific Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 Thermo Fisher Scientific Recent Developments and Future Plans
2.9 AGC Biologics
2.9.1 AGC Biologics Details
2.9.2 AGC Biologics Major Business
2.9.3 AGC Biologics Biopharmaceutical and Bio-CDMO Product and Solutions
2.9.4 AGC Biologics Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 AGC Biologics Recent Developments and Future Plans
2.10 Rentschler Biopharma
2.10.1 Rentschler Biopharma Details
2.10.2 Rentschler Biopharma Major Business
2.10.3 Rentschler Biopharma Biopharmaceutical and Bio-CDMO Product and Solutions
2.10.4 Rentschler Biopharma Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 Rentschler Biopharma Recent Developments and Future Plans
2.11 KBI Biopharma
2.11.1 KBI Biopharma Details
2.11.2 KBI Biopharma Major Business
2.11.3 KBI Biopharma Biopharmaceutical and Bio-CDMO Product and Solutions
2.11.4 KBI Biopharma Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2021-2026)
2.11.5 KBI Biopharma Recent Developments and Future Plans
2.12 Siegfried
2.12.1 Siegfried Details
2.12.2 Siegfried Major Business
2.12.3 Siegfried Biopharmaceutical and Bio-CDMO Product and Solutions
2.12.4 Siegfried Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2021-2026)
2.12.5 Siegfried Recent Developments and Future Plans
2.13 Aenova Group
2.13.1 Aenova Group Details
2.13.2 Aenova Group Major Business
2.13.3 Aenova Group Biopharmaceutical and Bio-CDMO Product and Solutions
2.13.4 Aenova Group Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2021-2026)
2.13.5 Aenova Group Recent Developments and Future Plans
2.14 GenScript
2.14.1 GenScript Details
2.14.2 GenScript Major Business
2.14.3 GenScript Biopharmaceutical and Bio-CDMO Product and Solutions
2.14.4 GenScript Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2021-2026)
2.14.5 GenScript Recent Developments and Future Plans
2.15 ProBioGen
2.15.1 ProBioGen Details
2.15.2 ProBioGen Major Business
2.15.3 ProBioGen Biopharmaceutical and Bio-CDMO Product and Solutions
2.15.4 ProBioGen Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2021-2026)
2.15.5 ProBioGen Recent Developments and Future Plans
2.16 Northway Biotech
2.16.1 Northway Biotech Details
2.16.2 Northway Biotech Major Business
2.16.3 Northway Biotech Biopharmaceutical and Bio-CDMO Product and Solutions
2.16.4 Northway Biotech Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2021-2026)
2.16.5 Northway Biotech Recent Developments and Future Plans
2.17 3P Biopharmaceuticals
2.17.1 3P Biopharmaceuticals Details
2.17.2 3P Biopharmaceuticals Major Business
2.17.3 3P Biopharmaceuticals Biopharmaceutical and Bio-CDMO Product and Solutions
2.17.4 3P Biopharmaceuticals Biopharmaceutical and Bio-CDMO Revenue, Gross Margin and Market Share (2021-2026)
2.17.5 3P Biopharmaceuticals Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Biopharmaceutical and Bio-CDMO Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
3.2.1 Market Share of Biopharmaceutical and Bio-CDMO by Company Revenue
3.2.2 Top 3 Biopharmaceutical and Bio-CDMO Players Market Share in 2025
3.2.3 Top 6 Biopharmaceutical and Bio-CDMO Players Market Share in 2025
3.3 Biopharmaceutical and Bio-CDMO Market: Overall Company Footprint Analysis
3.3.1 Biopharmaceutical and Bio-CDMO Market: Region Footprint
3.3.2 Biopharmaceutical and Bio-CDMO Market: Company Product Type Footprint
3.3.3 Biopharmaceutical and Bio-CDMO Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Biopharmaceutical and Bio-CDMO Consumption Value and Market Share by Type (2021-2026)
4.2 Global Biopharmaceutical and Bio-CDMO Market Forecast by Type (2027-2032)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Biopharmaceutical and Bio-CDMO Consumption Value Market Share by Application (2021-2026)
5.2 Global Biopharmaceutical and Bio-CDMO Market Forecast by Application (2027-2032)
6 NORTH AMERICA
6.1 North America Biopharmaceutical and Bio-CDMO Consumption Value by Type (2021-2032)
6.2 North America Biopharmaceutical and Bio-CDMO Market Size by Application (2021-2032)
6.3 North America Biopharmaceutical and Bio-CDMO Market Size by Country
6.3.1 North America Biopharmaceutical and Bio-CDMO Consumption Value by Country (2021-2032)
6.3.2 United States Biopharmaceutical and Bio-CDMO Market Size and Forecast (2021-2032)
6.3.3 Canada Biopharmaceutical and Bio-CDMO Market Size and Forecast (2021-2032)
6.3.4 Mexico Biopharmaceutical and Bio-CDMO Market Size and Forecast (2021-2032)
7 EUROPE
7.1 Europe Biopharmaceutical and Bio-CDMO Consumption Value by Type (2021-2032)
7.2 Europe Biopharmaceutical and Bio-CDMO Consumption Value by Application (2021-2032)
7.3 Europe Biopharmaceutical and Bio-CDMO Market Size by Country
7.3.1 Europe Biopharmaceutical and Bio-CDMO Consumption Value by Country (2021-2032)
7.3.2 Germany Biopharmaceutical and Bio-CDMO Market Size and Forecast (2021-2032)
7.3.3 France Biopharmaceutical and Bio-CDMO Market Size and Forecast (2021-2032)
7.3.4 United Kingdom Biopharmaceutical and Bio-CDMO Market Size and Forecast (2021-2032)
7.3.5 Russia Biopharmaceutical and Bio-CDMO Market Size and Forecast (2021-2032)
7.3.6 Italy Biopharmaceutical and Bio-CDMO Market Size and Forecast (2021-2032)
8 ASIA-PACIFIC
8.1 Asia-Pacific Biopharmaceutical and Bio-CDMO Consumption Value by Type (2021-2032)
8.2 Asia-Pacific Biopharmaceutical and Bio-CDMO Consumption Value by Application (2021-2032)
8.3 Asia-Pacific Biopharmaceutical and Bio-CDMO Market Size by Region
8.3.1 Asia-Pacific Biopharmaceutical and Bio-CDMO Consumption Value by Region (2021-2032)
8.3.2 China Biopharmaceutical and Bio-CDMO Market Size and Forecast (2021-2032)
8.3.3 Japan Biopharmaceutical and Bio-CDMO Market Size and Forecast (2021-2032)
8.3.4 South Korea Biopharmaceutical and Bio-CDMO Market Size and Forecast (2021-2032)
8.3.5 India Biopharmaceutical and Bio-CDMO Market Size and Forecast (2021-2032)
8.3.6 Southeast Asia Biopharmaceutical and Bio-CDMO Market Size and Forecast (2021-2032)
8.3.7 Australia Biopharmaceutical and Bio-CDMO Market Size and Forecast (2021-2032)
9 SOUTH AMERICA
9.1 South America Biopharmaceutical and Bio-CDMO Consumption Value by Type (2021-2032)
9.2 South America Biopharmaceutical and Bio-CDMO Consumption Value by Application (2021-2032)
9.3 South America Biopharmaceutical and Bio-CDMO Market Size by Country
9.3.1 South America Biopharmaceutical and Bio-CDMO Consumption Value by Country (2021-2032)
9.3.2 Brazil Biopharmaceutical and Bio-CDMO Market Size and Forecast (2021-2032)
9.3.3 Argentina Biopharmaceutical and Bio-CDMO Market Size and Forecast (2021-2032)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Biopharmaceutical and Bio-CDMO Consumption Value by Type (2021-2032)
10.2 Middle East & Africa Biopharmaceutical and Bio-CDMO Consumption Value by Application (2021-2032)
10.3 Middle East & Africa Biopharmaceutical and Bio-CDMO Market Size by Country
10.3.1 Middle East & Africa Biopharmaceutical and Bio-CDMO Consumption Value by Country (2021-2032)
10.3.2 Turkey Biopharmaceutical and Bio-CDMO Market Size and Forecast (2021-2032)
10.3.3 Saudi Arabia Biopharmaceutical and Bio-CDMO Market Size and Forecast (2021-2032)
10.3.4 UAE Biopharmaceutical and Bio-CDMO Market Size and Forecast (2021-2032)
11 MARKET DYNAMICS
11.1 Biopharmaceutical and Bio-CDMO Market Drivers
11.2 Biopharmaceutical and Bio-CDMO Market Restraints
11.3 Biopharmaceutical and Bio-CDMO Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Biopharmaceutical and Bio-CDMO Industry Chain
12.2 Biopharmaceutical and Bio-CDMO Upstream Analysis
12.3 Biopharmaceutical and Bio-CDMO Midstream Analysis
12.4 Biopharmaceutical and Bio-CDMO Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF FIGURES
Table 1. Global Biopharmaceutical and Bio-CDMO Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Biopharmaceutical and Bio-CDMO Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 3. Global Biopharmaceutical and Bio-CDMO Consumption Value by Region (2021-2026) & (USD Million)
Table 4. Global Biopharmaceutical and Bio-CDMO Consumption Value by Region (2027-2032) & (USD Million)
Table 5. Lonza Company Information, Head Office, and Major Competitors
Table 6. Lonza Major Business
Table 7. Lonza Biopharmaceutical and Bio-CDMO Product and Solutions
Table 8. Lonza Biopharmaceutical and Bio-CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 9. Lonza Recent Developments and Future Plans
Table 10. Catalent Company Information, Head Office, and Major Competitors
Table 11. Catalent Major Business
Table 12. Catalent Biopharmaceutical and Bio-CDMO Product and Solutions
Table 13. Catalent Biopharmaceutical and Bio-CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 14. Catalent Recent Developments and Future Plans
Table 15. Samsung Biologics Company Information, Head Office, and Major Competitors
Table 16. Samsung Biologics Major Business
Table 17. Samsung Biologics Biopharmaceutical and Bio-CDMO Product and Solutions
Table 18. Samsung Biologics Biopharmaceutical and Bio-CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 19. FUJIFILM Diosynth Biotechnologies Company Information, Head Office, and Major Competitors
Table 20. FUJIFILM Diosynth Biotechnologies Major Business
Table 21. FUJIFILM Diosynth Biotechnologies Biopharmaceutical and Bio-CDMO Product and Solutions
Table 22. FUJIFILM Diosynth Biotechnologies Biopharmaceutical and Bio-CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 23. FUJIFILM Diosynth Biotechnologies Recent Developments and Future Plans
Table 24. Boehringer Ingelheim Company Information, Head Office, and Major Competitors
Table 25. Boehringer Ingelheim Major Business
Table 26. Boehringer Ingelheim Biopharmaceutical and Bio-CDMO Product and Solutions
Table 27. Boehringer Ingelheim Biopharmaceutical and Bio-CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 28. Boehringer Ingelheim Recent Developments and Future Plans
Table 29. WuXi Biologics Company Information, Head Office, and Major Competitors
Table 30. WuXi Biologics Major Business
Table 31. WuXi Biologics Biopharmaceutical and Bio-CDMO Product and Solutions
Table 32. WuXi Biologics Biopharmaceutical and Bio-CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 33. WuXi Biologics Recent Developments and Future Plans
Table 34. Recipharm Company Information, Head Office, and Major Competitors
Table 35. Recipharm Major Business
Table 36. Recipharm Biopharmaceutical and Bio-CDMO Product and Solutions
Table 37. Recipharm Biopharmaceutical and Bio-CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 38. Recipharm Recent Developments and Future Plans
Table 39. Thermo Fisher Scientific Company Information, Head Office, and Major Competitors
Table 40. Thermo Fisher Scientific Major Business
Table 41. Thermo Fisher Scientific Biopharmaceutical and Bio-CDMO Product and Solutions
Table 42. Thermo Fisher Scientific Biopharmaceutical and Bio-CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 43. Thermo Fisher Scientific Recent Developments and Future Plans
Table 44. AGC Biologics Company Information, Head Office, and Major Competitors
Table 45. AGC Biologics Major Business
Table 46. AGC Biologics Biopharmaceutical and Bio-CDMO Product and Solutions
Table 47. AGC Biologics Biopharmaceutical and Bio-CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 48. AGC Biologics Recent Developments and Future Plans
Table 49. Rentschler Biopharma Company Information, Head Office, and Major Competitors
Table 50. Rentschler Biopharma Major Business
Table 51. Rentschler Biopharma Biopharmaceutical and Bio-CDMO Product and Solutions
Table 52. Rentschler Biopharma Biopharmaceutical and Bio-CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 53. Rentschler Biopharma Recent Developments and Future Plans
Table 54. KBI Biopharma Company Information, Head Office, and Major Competitors
Table 55. KBI Biopharma Major Business
Table 56. KBI Biopharma Biopharmaceutical and Bio-CDMO Product and Solutions
Table 57. KBI Biopharma Biopharmaceutical and Bio-CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 58. KBI Biopharma Recent Developments and Future Plans
Table 59. Siegfried Company Information, Head Office, and Major Competitors
Table 60. Siegfried Major Business
Table 61. Siegfried Biopharmaceutical and Bio-CDMO Product and Solutions
Table 62. Siegfried Biopharmaceutical and Bio-CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 63. Siegfried Recent Developments and Future Plans
Table 64. Aenova Group Company Information, Head Office, and Major Competitors
Table 65. Aenova Group Major Business
Table 66. Aenova Group Biopharmaceutical and Bio-CDMO Product and Solutions
Table 67. Aenova Group Biopharmaceutical and Bio-CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 68. Aenova Group Recent Developments and Future Plans
Table 69. GenScript Company Information, Head Office, and Major Competitors
Table 70. GenScript Major Business
Table 71. GenScript Biopharmaceutical and Bio-CDMO Product and Solutions
Table 72. GenScript Biopharmaceutical and Bio-CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 73. GenScript Recent Developments and Future Plans
Table 74. ProBioGen Company Information, Head Office, and Major Competitors
Table 75. ProBioGen Major Business
Table 76. ProBioGen Biopharmaceutical and Bio-CDMO Product and Solutions
Table 77. ProBioGen Biopharmaceutical and Bio-CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 78. ProBioGen Recent Developments and Future Plans
Table 79. Northway Biotech Company Information, Head Office, and Major Competitors
Table 80. Northway Biotech Major Business
Table 81. Northway Biotech Biopharmaceutical and Bio-CDMO Product and Solutions
Table 82. Northway Biotech Biopharmaceutical and Bio-CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 83. Northway Biotech Recent Developments and Future Plans
Table 84. 3P Biopharmaceuticals Company Information, Head Office, and Major Competitors
Table 85. 3P Biopharmaceuticals Major Business
Table 86. 3P Biopharmaceuticals Biopharmaceutical and Bio-CDMO Product and Solutions
Table 87. 3P Biopharmaceuticals Biopharmaceutical and Bio-CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 88. 3P Biopharmaceuticals Recent Developments and Future Plans
Table 89. Global Biopharmaceutical and Bio-CDMO Revenue (USD Million) by Players (2021-2026)
Table 90. Global Biopharmaceutical and Bio-CDMO Revenue Share by Players (2021-2026)
Table 91. Breakdown of Biopharmaceutical and Bio-CDMO by Company Type (Tier 1, Tier 2, and Tier 3)
Table 92. Market Position of Players in Biopharmaceutical and Bio-CDMO, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 93. Head Office of Key Biopharmaceutical and Bio-CDMO Players
Table 94. Biopharmaceutical and Bio-CDMO Market: Company Product Type Footprint
Table 95. Biopharmaceutical and Bio-CDMO Market: Company Product Application Footprint
Table 96. Biopharmaceutical and Bio-CDMO New Market Entrants and Barriers to Market Entry
Table 97. Biopharmaceutical and Bio-CDMO Mergers, Acquisition, Agreements, and Collaborations
Table 98. Global Biopharmaceutical and Bio-CDMO Consumption Value (USD Million) by Type (2021-2026)
Table 99. Global Biopharmaceutical and Bio-CDMO Consumption Value Share by Type (2021-2026)
Table 100. Global Biopharmaceutical and Bio-CDMO Consumption Value Forecast by Type (2027-2032)
Table 101. Global Biopharmaceutical and Bio-CDMO Consumption Value by Application (2021-2026)
Table 102. Global Biopharmaceutical and Bio-CDMO Consumption Value Forecast by Application (2027-2032)
Table 103. North America Biopharmaceutical and Bio-CDMO Consumption Value by Type (2021-2026) & (USD Million)
Table 104. North America Biopharmaceutical and Bio-CDMO Consumption Value by Type (2027-2032) & (USD Million)
Table 105. North America Biopharmaceutical and Bio-CDMO Consumption Value by Application (2021-2026) & (USD Million)
Table 106. North America Biopharmaceutical and Bio-CDMO Consumption Value by Application (2027-2032) & (USD Million)
Table 107. North America Biopharmaceutical and Bio-CDMO Consumption Value by Country (2021-2026) & (USD Million)
Table 108. North America Biopharmaceutical and Bio-CDMO Consumption Value by Country (2027-2032) & (USD Million)
Table 109. Europe Biopharmaceutical and Bio-CDMO Consumption Value by Type (2021-2026) & (USD Million)
Table 110. Europe Biopharmaceutical and Bio-CDMO Consumption Value by Type (2027-2032) & (USD Million)
Table 111. Europe Biopharmaceutical and Bio-CDMO Consumption Value by Application (2021-2026) & (USD Million)
Table 112. Europe Biopharmaceutical and Bio-CDMO Consumption Value by Application (2027-2032) & (USD Million)
Table 113. Europe Biopharmaceutical and Bio-CDMO Consumption Value by Country (2021-2026) & (USD Million)
Table 114. Europe Biopharmaceutical and Bio-CDMO Consumption Value by Country (2027-2032) & (USD Million)
Table 115. Asia-Pacific Biopharmaceutical and Bio-CDMO Consumption Value by Type (2021-2026) & (USD Million)
Table 116. Asia-Pacific Biopharmaceutical and Bio-CDMO Consumption Value by Type (2027-2032) & (USD Million)
Table 117. Asia-Pacific Biopharmaceutical and Bio-CDMO Consumption Value by Application (2021-2026) & (USD Million)
Table 118. Asia-Pacific Biopharmaceutical and Bio-CDMO Consumption Value by Application (2027-2032) & (USD Million)
Table 119. Asia-Pacific Biopharmaceutical and Bio-CDMO Consumption Value by Region (2021-2026) & (USD Million)
Table 120. Asia-Pacific Biopharmaceutical and Bio-CDMO Consumption Value by Region (2027-2032) & (USD Million)
Table 121. South America Biopharmaceutical and Bio-CDMO Consumption Value by Type (2021-2026) & (USD Million)
Table 122. South America Biopharmaceutical and Bio-CDMO Consumption Value by Type (2027-2032) & (USD Million)
Table 123. South America Biopharmaceutical and Bio-CDMO Consumption Value by Application (2021-2026) & (USD Million)
Table 124. South America Biopharmaceutical and Bio-CDMO Consumption Value by Application (2027-2032) & (USD Million)
Table 125. South America Biopharmaceutical and Bio-CDMO Consumption Value by Country (2021-2026) & (USD Million)
Table 126. South America Biopharmaceutical and Bio-CDMO Consumption Value by Country (2027-2032) & (USD Million)
Table 127. Middle East & Africa Biopharmaceutical and Bio-CDMO Consumption Value by Type (2021-2026) & (USD Million)
Table 128. Middle East & Africa Biopharmaceutical and Bio-CDMO Consumption Value by Type (2027-2032) & (USD Million)
Table 129. Middle East & Africa Biopharmaceutical and Bio-CDMO Consumption Value by Application (2021-2026) & (USD Million)
Table 130. Middle East & Africa Biopharmaceutical and Bio-CDMO Consumption Value by Application (2027-2032) & (USD Million)
Table 131. Middle East & Africa Biopharmaceutical and Bio-CDMO Consumption Value by Country (2021-2026) & (USD Million)
Table 132. Middle East & Africa Biopharmaceutical and Bio-CDMO Consumption Value by Country (2027-2032) & (USD Million)
Table 133. Global Key Players of Biopharmaceutical and Bio-CDMO Upstream (Raw Materials)
Table 134. Global Biopharmaceutical and Bio-CDMO Typical Customers
LIST OF FIGURES
Figure 1. Biopharmaceutical and Bio-CDMO Picture
Figure 2. Global Biopharmaceutical and Bio-CDMO Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Biopharmaceutical and Bio-CDMO Consumption Value Market Share by Type in 2025
Figure 4. Cell and Gene Therapies
Figure 5. Antibodies
Figure 6. Vaccines
Figure 7. Other
Figure 8. Global Biopharmaceutical and Bio-CDMO Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 9. Biopharmaceutical and Bio-CDMO Consumption Value Market Share by Application in 2025
Figure 10. SMBs Picture
Figure 11. Large Companies Picture
Figure 12. Global Biopharmaceutical and Bio-CDMO Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 13. Global Biopharmaceutical and Bio-CDMO Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 14. Global Market Biopharmaceutical and Bio-CDMO Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)
Figure 15. Global Biopharmaceutical and Bio-CDMO Consumption Value Market Share by Region (2021-2032)
Figure 16. Global Biopharmaceutical and Bio-CDMO Consumption Value Market Share by Region in 2025
Figure 17. North America Biopharmaceutical and Bio-CDMO Consumption Value (2021-2032) & (USD Million)
Figure 18. Europe Biopharmaceutical and Bio-CDMO Consumption Value (2021-2032) & (USD Million)
Figure 19. Asia-Pacific Biopharmaceutical and Bio-CDMO Consumption Value (2021-2032) & (USD Million)
Figure 20. South America Biopharmaceutical and Bio-CDMO Consumption Value (2021-2032) & (USD Million)
Figure 21. Middle East & Africa Biopharmaceutical and Bio-CDMO Consumption Value (2021-2032) & (USD Million)
Figure 22. Company Three Recent Developments and Future Plans
Figure 23. Global Biopharmaceutical and Bio-CDMO Revenue Share by Players in 2025
Figure 24. Biopharmaceutical and Bio-CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025
Figure 25. Market Share of Biopharmaceutical and Bio-CDMO by Player Revenue in 2025
Figure 26. Top 3 Biopharmaceutical and Bio-CDMO Players Market Share in 2025
Figure 27. Top 6 Biopharmaceutical and Bio-CDMO Players Market Share in 2025
Figure 28. Global Biopharmaceutical and Bio-CDMO Consumption Value Share by Type (2021-2026)
Figure 29. Global Biopharmaceutical and Bio-CDMO Market Share Forecast by Type (2027-2032)
Figure 30. Global Biopharmaceutical and Bio-CDMO Consumption Value Share by Application (2021-2026)
Figure 31. Global Biopharmaceutical and Bio-CDMO Market Share Forecast by Application (2027-2032)
Figure 32. North America Biopharmaceutical and Bio-CDMO Consumption Value Market Share by Type (2021-2032)
Figure 33. North America Biopharmaceutical and Bio-CDMO Consumption Value Market Share by Application (2021-2032)
Figure 34. North America Biopharmaceutical and Bio-CDMO Consumption Value Market Share by Country (2021-2032)
Figure 35. United States Biopharmaceutical and Bio-CDMO Consumption Value (2021-2032) & (USD Million)
Figure 36. Canada Biopharmaceutical and Bio-CDMO Consumption Value (2021-2032) & (USD Million)
Figure 37. Mexico Biopharmaceutical and Bio-CDMO Consumption Value (2021-2032) & (USD Million)
Figure 38. Europe Biopharmaceutical and Bio-CDMO Consumption Value Market Share by Type (2021-2032)
Figure 39. Europe Biopharmaceutical and Bio-CDMO Consumption Value Market Share by Application (2021-2032)
Figure 40. Europe Biopharmaceutical and Bio-CDMO Consumption Value Market Share by Country (2021-2032)
Figure 41. Germany Biopharmaceutical and Bio-CDMO Consumption Value (2021-2032) & (USD Million)
Figure 42. France Biopharmaceutical and Bio-CDMO Consumption Value (2021-2032) & (USD Million)
Figure 43. United Kingdom Biopharmaceutical and Bio-CDMO Consumption Value (2021-2032) & (USD Million)
Figure 44. Russia Biopharmaceutical and Bio-CDMO Consumption Value (2021-2032) & (USD Million)
Figure 45. Italy Biopharmaceutical and Bio-CDMO Consumption Value (2021-2032) & (USD Million)
Figure 46. Asia-Pacific Biopharmaceutical and Bio-CDMO Consumption Value Market Share by Type (2021-2032)
Figure 47. Asia-Pacific Biopharmaceutical and Bio-CDMO Consumption Value Market Share by Application (2021-2032)
Figure 48. Asia-Pacific Biopharmaceutical and Bio-CDMO Consumption Value Market Share by Region (2021-2032)
Figure 49. China Biopharmaceutical and Bio-CDMO Consumption Value (2021-2032) & (USD Million)
Figure 50. Japan Biopharmaceutical and Bio-CDMO Consumption Value (2021-2032) & (USD Million)
Figure 51. South Korea Biopharmaceutical and Bio-CDMO Consumption Value (2021-2032) & (USD Million)
Figure 52. India Biopharmaceutical and Bio-CDMO Consumption Value (2021-2032) & (USD Million)
Figure 53. Southeast Asia Biopharmaceutical and Bio-CDMO Consumption Value (2021-2032) & (USD Million)
Figure 54. Australia Biopharmaceutical and Bio-CDMO Consumption Value (2021-2032) & (USD Million)
Figure 55. South America Biopharmaceutical and Bio-CDMO Consumption Value Market Share by Type (2021-2032)
Figure 56. South America Biopharmaceutical and Bio-CDMO Consumption Value Market Share by Application (2021-2032)
Figure 57. South America Biopharmaceutical and Bio-CDMO Consumption Value Market Share by Country (2021-2032)
Figure 58. Brazil Biopharmaceutical and Bio-CDMO Consumption Value (2021-2032) & (USD Million)
Figure 59. Argentina Biopharmaceutical and Bio-CDMO Consumption Value (2021-2032) & (USD Million)
Figure 60. Middle East & Africa Biopharmaceutical and Bio-CDMO Consumption Value Market Share by Type (2021-2032)
Figure 61. Middle East & Africa Biopharmaceutical and Bio-CDMO Consumption Value Market Share by Application (2021-2032)
Figure 62. Middle East & Africa Biopharmaceutical and Bio-CDMO Consumption Value Market Share by Country (2021-2032)
Figure 63. Turkey Biopharmaceutical and Bio-CDMO Consumption Value (2021-2032) & (USD Million)
Figure 64. Saudi Arabia Biopharmaceutical and Bio-CDMO Consumption Value (2021-2032) & (USD Million)
Figure 65. UAE Biopharmaceutical and Bio-CDMO Consumption Value (2021-2032) & (USD Million)
Figure 66. Biopharmaceutical and Bio-CDMO Market Drivers
Figure 67. Biopharmaceutical and Bio-CDMO Market Restraints
Figure 68. Biopharmaceutical and Bio-CDMO Market Trends
Figure 69. Porters Five Forces Analysis
Figure 70. Biopharmaceutical and Bio-CDMO Industrial Chain
Figure 71. Methodology
Figure 72. Research Process and Data Source
Table 1. Global Biopharmaceutical and Bio-CDMO Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Biopharmaceutical and Bio-CDMO Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 3. Global Biopharmaceutical and Bio-CDMO Consumption Value by Region (2021-2026) & (USD Million)
Table 4. Global Biopharmaceutical and Bio-CDMO Consumption Value by Region (2027-2032) & (USD Million)
Table 5. Lonza Company Information, Head Office, and Major Competitors
Table 6. Lonza Major Business
Table 7. Lonza Biopharmaceutical and Bio-CDMO Product and Solutions
Table 8. Lonza Biopharmaceutical and Bio-CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 9. Lonza Recent Developments and Future Plans
Table 10. Catalent Company Information, Head Office, and Major Competitors
Table 11. Catalent Major Business
Table 12. Catalent Biopharmaceutical and Bio-CDMO Product and Solutions
Table 13. Catalent Biopharmaceutical and Bio-CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 14. Catalent Recent Developments and Future Plans
Table 15. Samsung Biologics Company Information, Head Office, and Major Competitors
Table 16. Samsung Biologics Major Business
Table 17. Samsung Biologics Biopharmaceutical and Bio-CDMO Product and Solutions
Table 18. Samsung Biologics Biopharmaceutical and Bio-CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 19. FUJIFILM Diosynth Biotechnologies Company Information, Head Office, and Major Competitors
Table 20. FUJIFILM Diosynth Biotechnologies Major Business
Table 21. FUJIFILM Diosynth Biotechnologies Biopharmaceutical and Bio-CDMO Product and Solutions
Table 22. FUJIFILM Diosynth Biotechnologies Biopharmaceutical and Bio-CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 23. FUJIFILM Diosynth Biotechnologies Recent Developments and Future Plans
Table 24. Boehringer Ingelheim Company Information, Head Office, and Major Competitors
Table 25. Boehringer Ingelheim Major Business
Table 26. Boehringer Ingelheim Biopharmaceutical and Bio-CDMO Product and Solutions
Table 27. Boehringer Ingelheim Biopharmaceutical and Bio-CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 28. Boehringer Ingelheim Recent Developments and Future Plans
Table 29. WuXi Biologics Company Information, Head Office, and Major Competitors
Table 30. WuXi Biologics Major Business
Table 31. WuXi Biologics Biopharmaceutical and Bio-CDMO Product and Solutions
Table 32. WuXi Biologics Biopharmaceutical and Bio-CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 33. WuXi Biologics Recent Developments and Future Plans
Table 34. Recipharm Company Information, Head Office, and Major Competitors
Table 35. Recipharm Major Business
Table 36. Recipharm Biopharmaceutical and Bio-CDMO Product and Solutions
Table 37. Recipharm Biopharmaceutical and Bio-CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 38. Recipharm Recent Developments and Future Plans
Table 39. Thermo Fisher Scientific Company Information, Head Office, and Major Competitors
Table 40. Thermo Fisher Scientific Major Business
Table 41. Thermo Fisher Scientific Biopharmaceutical and Bio-CDMO Product and Solutions
Table 42. Thermo Fisher Scientific Biopharmaceutical and Bio-CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 43. Thermo Fisher Scientific Recent Developments and Future Plans
Table 44. AGC Biologics Company Information, Head Office, and Major Competitors
Table 45. AGC Biologics Major Business
Table 46. AGC Biologics Biopharmaceutical and Bio-CDMO Product and Solutions
Table 47. AGC Biologics Biopharmaceutical and Bio-CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 48. AGC Biologics Recent Developments and Future Plans
Table 49. Rentschler Biopharma Company Information, Head Office, and Major Competitors
Table 50. Rentschler Biopharma Major Business
Table 51. Rentschler Biopharma Biopharmaceutical and Bio-CDMO Product and Solutions
Table 52. Rentschler Biopharma Biopharmaceutical and Bio-CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 53. Rentschler Biopharma Recent Developments and Future Plans
Table 54. KBI Biopharma Company Information, Head Office, and Major Competitors
Table 55. KBI Biopharma Major Business
Table 56. KBI Biopharma Biopharmaceutical and Bio-CDMO Product and Solutions
Table 57. KBI Biopharma Biopharmaceutical and Bio-CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 58. KBI Biopharma Recent Developments and Future Plans
Table 59. Siegfried Company Information, Head Office, and Major Competitors
Table 60. Siegfried Major Business
Table 61. Siegfried Biopharmaceutical and Bio-CDMO Product and Solutions
Table 62. Siegfried Biopharmaceutical and Bio-CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 63. Siegfried Recent Developments and Future Plans
Table 64. Aenova Group Company Information, Head Office, and Major Competitors
Table 65. Aenova Group Major Business
Table 66. Aenova Group Biopharmaceutical and Bio-CDMO Product and Solutions
Table 67. Aenova Group Biopharmaceutical and Bio-CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 68. Aenova Group Recent Developments and Future Plans
Table 69. GenScript Company Information, Head Office, and Major Competitors
Table 70. GenScript Major Business
Table 71. GenScript Biopharmaceutical and Bio-CDMO Product and Solutions
Table 72. GenScript Biopharmaceutical and Bio-CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 73. GenScript Recent Developments and Future Plans
Table 74. ProBioGen Company Information, Head Office, and Major Competitors
Table 75. ProBioGen Major Business
Table 76. ProBioGen Biopharmaceutical and Bio-CDMO Product and Solutions
Table 77. ProBioGen Biopharmaceutical and Bio-CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 78. ProBioGen Recent Developments and Future Plans
Table 79. Northway Biotech Company Information, Head Office, and Major Competitors
Table 80. Northway Biotech Major Business
Table 81. Northway Biotech Biopharmaceutical and Bio-CDMO Product and Solutions
Table 82. Northway Biotech Biopharmaceutical and Bio-CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 83. Northway Biotech Recent Developments and Future Plans
Table 84. 3P Biopharmaceuticals Company Information, Head Office, and Major Competitors
Table 85. 3P Biopharmaceuticals Major Business
Table 86. 3P Biopharmaceuticals Biopharmaceutical and Bio-CDMO Product and Solutions
Table 87. 3P Biopharmaceuticals Biopharmaceutical and Bio-CDMO Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 88. 3P Biopharmaceuticals Recent Developments and Future Plans
Table 89. Global Biopharmaceutical and Bio-CDMO Revenue (USD Million) by Players (2021-2026)
Table 90. Global Biopharmaceutical and Bio-CDMO Revenue Share by Players (2021-2026)
Table 91. Breakdown of Biopharmaceutical and Bio-CDMO by Company Type (Tier 1, Tier 2, and Tier 3)
Table 92. Market Position of Players in Biopharmaceutical and Bio-CDMO, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 93. Head Office of Key Biopharmaceutical and Bio-CDMO Players
Table 94. Biopharmaceutical and Bio-CDMO Market: Company Product Type Footprint
Table 95. Biopharmaceutical and Bio-CDMO Market: Company Product Application Footprint
Table 96. Biopharmaceutical and Bio-CDMO New Market Entrants and Barriers to Market Entry
Table 97. Biopharmaceutical and Bio-CDMO Mergers, Acquisition, Agreements, and Collaborations
Table 98. Global Biopharmaceutical and Bio-CDMO Consumption Value (USD Million) by Type (2021-2026)
Table 99. Global Biopharmaceutical and Bio-CDMO Consumption Value Share by Type (2021-2026)
Table 100. Global Biopharmaceutical and Bio-CDMO Consumption Value Forecast by Type (2027-2032)
Table 101. Global Biopharmaceutical and Bio-CDMO Consumption Value by Application (2021-2026)
Table 102. Global Biopharmaceutical and Bio-CDMO Consumption Value Forecast by Application (2027-2032)
Table 103. North America Biopharmaceutical and Bio-CDMO Consumption Value by Type (2021-2026) & (USD Million)
Table 104. North America Biopharmaceutical and Bio-CDMO Consumption Value by Type (2027-2032) & (USD Million)
Table 105. North America Biopharmaceutical and Bio-CDMO Consumption Value by Application (2021-2026) & (USD Million)
Table 106. North America Biopharmaceutical and Bio-CDMO Consumption Value by Application (2027-2032) & (USD Million)
Table 107. North America Biopharmaceutical and Bio-CDMO Consumption Value by Country (2021-2026) & (USD Million)
Table 108. North America Biopharmaceutical and Bio-CDMO Consumption Value by Country (2027-2032) & (USD Million)
Table 109. Europe Biopharmaceutical and Bio-CDMO Consumption Value by Type (2021-2026) & (USD Million)
Table 110. Europe Biopharmaceutical and Bio-CDMO Consumption Value by Type (2027-2032) & (USD Million)
Table 111. Europe Biopharmaceutical and Bio-CDMO Consumption Value by Application (2021-2026) & (USD Million)
Table 112. Europe Biopharmaceutical and Bio-CDMO Consumption Value by Application (2027-2032) & (USD Million)
Table 113. Europe Biopharmaceutical and Bio-CDMO Consumption Value by Country (2021-2026) & (USD Million)
Table 114. Europe Biopharmaceutical and Bio-CDMO Consumption Value by Country (2027-2032) & (USD Million)
Table 115. Asia-Pacific Biopharmaceutical and Bio-CDMO Consumption Value by Type (2021-2026) & (USD Million)
Table 116. Asia-Pacific Biopharmaceutical and Bio-CDMO Consumption Value by Type (2027-2032) & (USD Million)
Table 117. Asia-Pacific Biopharmaceutical and Bio-CDMO Consumption Value by Application (2021-2026) & (USD Million)
Table 118. Asia-Pacific Biopharmaceutical and Bio-CDMO Consumption Value by Application (2027-2032) & (USD Million)
Table 119. Asia-Pacific Biopharmaceutical and Bio-CDMO Consumption Value by Region (2021-2026) & (USD Million)
Table 120. Asia-Pacific Biopharmaceutical and Bio-CDMO Consumption Value by Region (2027-2032) & (USD Million)
Table 121. South America Biopharmaceutical and Bio-CDMO Consumption Value by Type (2021-2026) & (USD Million)
Table 122. South America Biopharmaceutical and Bio-CDMO Consumption Value by Type (2027-2032) & (USD Million)
Table 123. South America Biopharmaceutical and Bio-CDMO Consumption Value by Application (2021-2026) & (USD Million)
Table 124. South America Biopharmaceutical and Bio-CDMO Consumption Value by Application (2027-2032) & (USD Million)
Table 125. South America Biopharmaceutical and Bio-CDMO Consumption Value by Country (2021-2026) & (USD Million)
Table 126. South America Biopharmaceutical and Bio-CDMO Consumption Value by Country (2027-2032) & (USD Million)
Table 127. Middle East & Africa Biopharmaceutical and Bio-CDMO Consumption Value by Type (2021-2026) & (USD Million)
Table 128. Middle East & Africa Biopharmaceutical and Bio-CDMO Consumption Value by Type (2027-2032) & (USD Million)
Table 129. Middle East & Africa Biopharmaceutical and Bio-CDMO Consumption Value by Application (2021-2026) & (USD Million)
Table 130. Middle East & Africa Biopharmaceutical and Bio-CDMO Consumption Value by Application (2027-2032) & (USD Million)
Table 131. Middle East & Africa Biopharmaceutical and Bio-CDMO Consumption Value by Country (2021-2026) & (USD Million)
Table 132. Middle East & Africa Biopharmaceutical and Bio-CDMO Consumption Value by Country (2027-2032) & (USD Million)
Table 133. Global Key Players of Biopharmaceutical and Bio-CDMO Upstream (Raw Materials)
Table 134. Global Biopharmaceutical and Bio-CDMO Typical Customers
LIST OF FIGURES
Figure 1. Biopharmaceutical and Bio-CDMO Picture
Figure 2. Global Biopharmaceutical and Bio-CDMO Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Biopharmaceutical and Bio-CDMO Consumption Value Market Share by Type in 2025
Figure 4. Cell and Gene Therapies
Figure 5. Antibodies
Figure 6. Vaccines
Figure 7. Other
Figure 8. Global Biopharmaceutical and Bio-CDMO Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 9. Biopharmaceutical and Bio-CDMO Consumption Value Market Share by Application in 2025
Figure 10. SMBs Picture
Figure 11. Large Companies Picture
Figure 12. Global Biopharmaceutical and Bio-CDMO Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 13. Global Biopharmaceutical and Bio-CDMO Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 14. Global Market Biopharmaceutical and Bio-CDMO Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)
Figure 15. Global Biopharmaceutical and Bio-CDMO Consumption Value Market Share by Region (2021-2032)
Figure 16. Global Biopharmaceutical and Bio-CDMO Consumption Value Market Share by Region in 2025
Figure 17. North America Biopharmaceutical and Bio-CDMO Consumption Value (2021-2032) & (USD Million)
Figure 18. Europe Biopharmaceutical and Bio-CDMO Consumption Value (2021-2032) & (USD Million)
Figure 19. Asia-Pacific Biopharmaceutical and Bio-CDMO Consumption Value (2021-2032) & (USD Million)
Figure 20. South America Biopharmaceutical and Bio-CDMO Consumption Value (2021-2032) & (USD Million)
Figure 21. Middle East & Africa Biopharmaceutical and Bio-CDMO Consumption Value (2021-2032) & (USD Million)
Figure 22. Company Three Recent Developments and Future Plans
Figure 23. Global Biopharmaceutical and Bio-CDMO Revenue Share by Players in 2025
Figure 24. Biopharmaceutical and Bio-CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025
Figure 25. Market Share of Biopharmaceutical and Bio-CDMO by Player Revenue in 2025
Figure 26. Top 3 Biopharmaceutical and Bio-CDMO Players Market Share in 2025
Figure 27. Top 6 Biopharmaceutical and Bio-CDMO Players Market Share in 2025
Figure 28. Global Biopharmaceutical and Bio-CDMO Consumption Value Share by Type (2021-2026)
Figure 29. Global Biopharmaceutical and Bio-CDMO Market Share Forecast by Type (2027-2032)
Figure 30. Global Biopharmaceutical and Bio-CDMO Consumption Value Share by Application (2021-2026)
Figure 31. Global Biopharmaceutical and Bio-CDMO Market Share Forecast by Application (2027-2032)
Figure 32. North America Biopharmaceutical and Bio-CDMO Consumption Value Market Share by Type (2021-2032)
Figure 33. North America Biopharmaceutical and Bio-CDMO Consumption Value Market Share by Application (2021-2032)
Figure 34. North America Biopharmaceutical and Bio-CDMO Consumption Value Market Share by Country (2021-2032)
Figure 35. United States Biopharmaceutical and Bio-CDMO Consumption Value (2021-2032) & (USD Million)
Figure 36. Canada Biopharmaceutical and Bio-CDMO Consumption Value (2021-2032) & (USD Million)
Figure 37. Mexico Biopharmaceutical and Bio-CDMO Consumption Value (2021-2032) & (USD Million)
Figure 38. Europe Biopharmaceutical and Bio-CDMO Consumption Value Market Share by Type (2021-2032)
Figure 39. Europe Biopharmaceutical and Bio-CDMO Consumption Value Market Share by Application (2021-2032)
Figure 40. Europe Biopharmaceutical and Bio-CDMO Consumption Value Market Share by Country (2021-2032)
Figure 41. Germany Biopharmaceutical and Bio-CDMO Consumption Value (2021-2032) & (USD Million)
Figure 42. France Biopharmaceutical and Bio-CDMO Consumption Value (2021-2032) & (USD Million)
Figure 43. United Kingdom Biopharmaceutical and Bio-CDMO Consumption Value (2021-2032) & (USD Million)
Figure 44. Russia Biopharmaceutical and Bio-CDMO Consumption Value (2021-2032) & (USD Million)
Figure 45. Italy Biopharmaceutical and Bio-CDMO Consumption Value (2021-2032) & (USD Million)
Figure 46. Asia-Pacific Biopharmaceutical and Bio-CDMO Consumption Value Market Share by Type (2021-2032)
Figure 47. Asia-Pacific Biopharmaceutical and Bio-CDMO Consumption Value Market Share by Application (2021-2032)
Figure 48. Asia-Pacific Biopharmaceutical and Bio-CDMO Consumption Value Market Share by Region (2021-2032)
Figure 49. China Biopharmaceutical and Bio-CDMO Consumption Value (2021-2032) & (USD Million)
Figure 50. Japan Biopharmaceutical and Bio-CDMO Consumption Value (2021-2032) & (USD Million)
Figure 51. South Korea Biopharmaceutical and Bio-CDMO Consumption Value (2021-2032) & (USD Million)
Figure 52. India Biopharmaceutical and Bio-CDMO Consumption Value (2021-2032) & (USD Million)
Figure 53. Southeast Asia Biopharmaceutical and Bio-CDMO Consumption Value (2021-2032) & (USD Million)
Figure 54. Australia Biopharmaceutical and Bio-CDMO Consumption Value (2021-2032) & (USD Million)
Figure 55. South America Biopharmaceutical and Bio-CDMO Consumption Value Market Share by Type (2021-2032)
Figure 56. South America Biopharmaceutical and Bio-CDMO Consumption Value Market Share by Application (2021-2032)
Figure 57. South America Biopharmaceutical and Bio-CDMO Consumption Value Market Share by Country (2021-2032)
Figure 58. Brazil Biopharmaceutical and Bio-CDMO Consumption Value (2021-2032) & (USD Million)
Figure 59. Argentina Biopharmaceutical and Bio-CDMO Consumption Value (2021-2032) & (USD Million)
Figure 60. Middle East & Africa Biopharmaceutical and Bio-CDMO Consumption Value Market Share by Type (2021-2032)
Figure 61. Middle East & Africa Biopharmaceutical and Bio-CDMO Consumption Value Market Share by Application (2021-2032)
Figure 62. Middle East & Africa Biopharmaceutical and Bio-CDMO Consumption Value Market Share by Country (2021-2032)
Figure 63. Turkey Biopharmaceutical and Bio-CDMO Consumption Value (2021-2032) & (USD Million)
Figure 64. Saudi Arabia Biopharmaceutical and Bio-CDMO Consumption Value (2021-2032) & (USD Million)
Figure 65. UAE Biopharmaceutical and Bio-CDMO Consumption Value (2021-2032) & (USD Million)
Figure 66. Biopharmaceutical and Bio-CDMO Market Drivers
Figure 67. Biopharmaceutical and Bio-CDMO Market Restraints
Figure 68. Biopharmaceutical and Bio-CDMO Market Trends
Figure 69. Porters Five Forces Analysis
Figure 70. Biopharmaceutical and Bio-CDMO Industrial Chain
Figure 71. Methodology
Figure 72. Research Process and Data Source
